Researchers at Sanford Burnham Prebys have identified a natural brain protein that appears to block the destructive tau tangles central to Alzheimer's disease and other dementias. The discovery, reported in Science Advances in July 2026, suggests a new avenue for developing therapies that could harness the brain's own defense mechanisms.
The protein in question, called SORLA, normally circulates throughout the nervous system. In Alzheimer's disease and related conditions known as tauopathies, tau proteins misfold and clump into toxic tangles inside nerve cells. These tangles disrupt neural communication and ultimately kill neurons, driving cognitive decline. Until now, researchers knew SORLA could suppress amyloid-beta, another hallmark of Alzheimer's, but its role in combating tau damage remained largely unexplored.
To test whether SORLA could protect against tau-driven neurodegeneration, the team bred mice engineered to produce excess human SORLA with mice that naturally develop tau tangles, brain shrinkage, and cognitive problems. The results were striking. Higher SORLA levels interfered with the toxic cascade that allows tau to accumulate. Specifically, the protein reduced excessive phosphorylation, a chemical modification that makes tau more likely to misfold, and it blocked malformed tau from acting as "seeds" that recruit other tau molecules into larger, more damaging clumps.
The protective effects rippled through the brain's circuitry. Mice with elevated SORLA maintained healthier synapses, the connection points where neurons communicate, and showed better preservation of synaptic plasticity, the brain's ability to strengthen or weaken those connections over time. Brain tissue also showed less atrophy compared to control animals.
The flip side was equally informative. Researchers also studied mice engineered to lack the Sorl1 gene that produces SORLA. These animals experienced exacerbated tau damage, underscoring how critical the protein is for brain protection. Some people naturally carry mutations that disrupt this gene, suggesting they may face heightened vulnerability to tauopathy.
To understand the mechanics behind SORLA's protective power, the team employed advanced cell sequencing and mapping techniques that measured protein production and gene activity at the level of individual cells. They discovered that SORLA prevents harmful changes in protein synthesis at synapses and suppresses multiple biological pathways implicated in tauopathy progression. The protein also quieted disease-related patterns of gene activity in glial cells, the support cells that nourish neurons and coordinate immune responses in the brain.
One particularly intriguing finding emerged from the analysis. When SORLA was absent, genes for plexin-B family receptors were abnormally activated. These receptors are already known targets of existing drugs used for other conditions. The researchers see potential in repurposing those medications to dampen glial cell overactivation and potentially reverse some of the damage in tau-related dementias.
The team's next steps involve studying human neurons and glial cells grafted into mouse brains to see how different SORLA mutations behave in a living disease environment. The distinction matters because human cells respond differently than mouse cells to molecular changes. Such experiments could reveal whether boosting SORLA or activating related pathways could become therapeutic strategies.
Author Jessica Williams: "This work reframes Alzheimer's research away from fighting tau alone and toward amplifying the brain's natural defenses, a shift that could crack open entirely new drug development pathways."
Comments